Medtronic Gains Offset by China VBP and Biologics

Medtronic reported FY 1Q23 orthopedic sales of $727.3 million, -4.1% compared to FY 1Q22.

The company estimates that it won share through its core spine offerings in the U.S., but volume-based procurement in China and unfavorable ordering patterns in biologics offset that strength. Medtronic expects incremental pressure from VBP as China...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us